Fig 2. Experimental approach for discriminating sera from control individuals and patients with TBI and post- concussion syndrome (PCS) sequelae.

(A) Flow chart for serum sample handling and mass spectrometry for binary patient/subject group analysis. Distinguishing control samples from TBI “most affected” samples is exhibited. (B) Peak Scoring for LOOCV (leave [one serum sample] out cross validation) procedure to classify mass peaks either “most affect” or control from a “left out” sample, over a narrow range (600–660 m/Z is displayed) of significant group discriminatory mass peaks. The PCV (peak classification value) example is exhibited on peak 635 which is used to classify “left out” peaks as either most affected (peak area above this PCV) or control (peak area at or below this PCV).